The safety of IFNα inhalation was demonstrated in two studies, which reported no difference in the proportion of COVID-19 patients receiving IFNα treatment between those with and without delayed-phase thrombocytopenia, nor between survivors and non-survivors [28,29]. The gene discussed is IFNA1; the disease is Thrombocytopenia.